Magno S, et al. - In this single center, controlled, randomized, open-label, cross-over clinical study, the researchers evaluated the lipid-lowering activity and safety of a dietary supplement containing monacolin K, L-arginine, coenzyme Q10 and ascorbic acid, named Argicolina (A), compared to a commercially available product containing monacolin K and coenzyme Q10, Normolip 5 (N). Twenty Caucasian outpatients aged 18–75 years with serum LDL-cholesterol (LDL-C) between 130 and 180 mg/dL were enrolled. The results obtained from the study proved the clinically meaningful LDL-C lowering properties of monacolin K. The novel association (A) of monacolin K with L-arginine, coenzime Q10 and ascorbic acid also produced a significant reduction of triglycerides without significant effects on HDL at variance with a supplement already in the market (N).